The company has a product pipeline of small molecule therapeutics that have shown strong potential in preclinical models. These therapeutics are the result of 20 years of innovative research funded by grants from the National Institute of Health. WavoDyne has entered into a licensing agreement with the University of Rochester Medical Center, which provides exclusivity on a series of patented drug candidates. The company plans to start Phase 1 clinical studies in 2016 for the treatment of Postoperative Cognitive Dysfunction and HIV Associated Neurocognitive Disorders. Their goal is to launch their first product for the treatment of Postoperative Cognitive Dysfunction in the 2021-2022 timeframe.